# Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia

> **NCT01709838** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 134 (actual)

## Conditions studied

- Non-transfusion Dependent Thalassemia

## Interventions

- **DRUG:** deferasirox

## Key facts

- **NCT ID:** NCT01709838
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-06
- **Primary completion:** 2015-01-03
- **Final completion:** 2019-01-17
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2019-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01709838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01709838, "Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT01709838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*